KRAS and pancreatic neoplasm: Among the 175 pancreatic cancer patients in TCGA PAAD datasets, 117 patients were with KRAS mutation, 108 patients were with TP53 mutation and 87 patients were with CDKN2A deletion (Figure 2B).